NCT01325896Unknown2 期
Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2002年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Time to Progression (TTP) and WHO (World Health Organization) Toxicity scale
研究概览
简要总结
- Multiple myeloma accounts for approximately 1% of all cancers and 10% of hematologic malignancies. Between 50 and 70% of symptomatic patients presented response to induction chemotherapy. The rate of complete responses (CR) achieved with standard induction of these treatments is less than 5% of cases and the median event-free survival between 2 and 3 years although most of the patients died from the disease.
- High dose chemotherapy with autologous stem cell transplant has improved the response rate and survival of patient with MM. However eventually all patients relapse with a median EFS between 40-50 months post-transplant.
- To improve these results and sustain remission, various maintenance treatment have been proposed as is the case of Interpheron alpha2b s.c. (Intron A) that has shown benefits in a meta-analysis.
- Intron A s.c. need administration of 3 days per week and is not well tolerated
- Recently a new formulation of Interpheron alpha2b is available. Conjugated with polietilenglicol (Pegintron) that need only one dose weekly and has not been tested in MM.
- The purpose of this study is to evaluate the role of Pegintron as maintenance after autologous transplant in MM
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≤ 65 years old diagnosed with multiple myeloma in stage II or III of Durie-Salmon staging.
- •Patients who have achieved a complete response, partial after a myelosuppressive chemotherapy treatment followed by infusion of peripheral blood progenitor cells as first-line treatment. The criteria used to define the complete or partial response are the EBMT, ABMTR IBMTR and set out in the criteria paper of Bladé J, Samson D, Reece D, et al 1998
- •Subjects must have a Karnofsky performance status ≥ 60% at the time of joining the program.
- •Subjects must have adequate renal and hepatic function, defined as <2 times the upper limit of normal laboratory.
- •Subjects must have adequate hematologic function, defined as: platelets> 50,000/μl, ≥Hemoglobin 9.0 g/dl, total leukocyte account> 2.000/μl
- •No history of any cancer within the past 5 years except squamous cell carcinoma or basal cell skin or cervical carcinoma in stage I or in situ.
- •No history of hypersensitivity to interferon alfa or any other part of the injection.
- •No severe clotting disorders, thrombophlebitis or pulmonary embolism, or decompensated liver disease.
- •Pregnant or lactating at the time of diagnosis can not participate in this therapeutic program. During the same, men and women participants should not conceive children. Also, women who become pregnant will be withdrawn from the protocol.
- •Obtaining informed consent.
排除标准
- •Patients > 65 years old.
- •Patients with multiple myeloma stage I of Durie-Salmon staging system.
- •Patients who have not achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by infusion of progenitor cells from peripheral blood autologous treatment of any kind is allowed intensification of chemotherapy and pretransplant conditioning regimen. The criteria used to define the complete or partial response are the EBMT, ABMTR IBMTR and set out in the criteria paper of Bladé J, Samson D, Reece D, et al 1998
- •Treatment with any investigational drug within 30 days prior to the addition to this protocol.
- •Subjects with severe cardiovascular disease.
- •Subjects with a history of neuropsychiatric disorder that requires hospitalization.
- •Subjects with thyroid dysfunction or uncontrolled diabetes mellitus (refractory to treatment).
- •Subjects with active infection and / or uncontrolled.
- •Pregnant or lactating women or women of childbearing age not practicing effective contraception.
- •Patients with previous psychiatric disease, especially moderate or severe depression or a history of severe psychiatric disorder, including psychosis, suicidal thoughts or suicide attempts. In severe depression cover the following points: (a) hospitalization for depression (b) electroconvulsive therapy for depression or (c) depression leading to the prolonged absence at work or to alter significantly the daily functions. Can be consider the entrance into the study of subjects with mild depression, where it is demonstrated by pre-treatment assessment individual's emotional state is clinically stable and in which case a treatment program formulated for the patient who will become part of the patient's medical record.
研究组 & 干预措施
All patients are receiving PEG-Intron
Other
干预措施: PEG-Intron sc injection (Drug)
结局指标
主要结局
Time to Progression (TTP) and WHO (World Health Organization) Toxicity scale
时间窗: three years
Evaluate the number of Participants with Adverse Events, and provide guidelines for treatment with PEG-Intron (either in association with corticosteroids and / or bisphosphonate), administered weekly to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen, followed by an infusion of autologous peripheral blood progenitor cell (PBSCT) as treatment intensification.
次要结局
- Increase of Response (anti-tumoral effect) and Dose Tolerance(three years)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple MyelomaMultiple MyelomaNCT04895410AbbVie8
已完成
2 期
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 AntibodyMultiple MyelomaNCT03525678GlaxoSmithKline221
终止
1 期
Panobinostat/Velcade in Multiple MyelomaMultiple MyelomaNCT00891033University of Arkansas12
已完成
2 期
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple MyelomaMultiple MyelomaNCT03224507University of Alabama at Birmingham123
终止
不适用
CAR-T Cells Therapy in Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma(MM)NCT03473496Zhujiang Hospital2